These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 36578130

  • 1. SARS-CoV-2 vaccine-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid.
    Nakahara Y, Yamane M, Sunada M, Aoyama Y.
    J Dermatol; 2023 Feb; 50(2):162-165. PubMed ID: 36578130
    [Abstract] [Full Text] [Related]

  • 2. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y, Nishie W, Izumi K, Shimizu H.
    Front Immunol; 2019 Feb; 10():1224. PubMed ID: 31191560
    [Abstract] [Full Text] [Related]

  • 3. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
    Sun L, Wang C, Wu C, Zhou Y, Wang C.
    Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
    [Abstract] [Full Text] [Related]

  • 4. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases.
    de Risi-Pugliese T, Cohen Aubart F, Haroche J, Moguelet P, Grootenboer-Mignot S, Mathian A, Ingen-Housz-Oro S, Hie M, Wendremaire N, Aucouturier F, Lepelletier F, Miyara M, Bader-Meunier B, Rémy P, Fabien N, Francès C, Barete S, Amoura Z.
    Semin Arthritis Rheum; 2018 Aug; 48(1):83-89. PubMed ID: 29191376
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A case of anti-laminin γ1 (p200) pemphigoid developed after dipeptidyl peptidase-4 inhibitor administration.
    Nakatani K, Noborio R, Nomura Y, Ueki Y, Kiyohara T, Hashimoto T.
    J Dermatol; 2024 Jun; 51(6):869-872. PubMed ID: 38214494
    [Abstract] [Full Text] [Related]

  • 7. Bullous Systemic Lupus Erythematosus as an Initial Manifestation of SLE.
    Fujimoto W, Hamada T, Yamada J, Matsuura H, Iwatsuki K.
    J Dermatol; 2005 Dec; 32(12):1021-7. PubMed ID: 16471470
    [Abstract] [Full Text] [Related]

  • 8. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y, Nishie W, Sato K, Hotta M, Izumi K, Ito K, Hosokawa K, Shimizu H.
    Front Immunol; 2018 Dec; 9():542. PubMed ID: 29706950
    [Abstract] [Full Text] [Related]

  • 9. Bullous systemic lupus erythematosus: An uncommon manifestation in pediatric population.
    Hasbún Z MT, Rollan MP, Chaparro R X, Fischer S C, Castrillón V A, González B S, Reculé F.
    Andes Pediatr; 2021 Jun; 92(3):428-433. PubMed ID: 34479250
    [Abstract] [Full Text] [Related]

  • 10. Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus.
    Grabell DA, Matthews LA, Yancey KB, Chong BF.
    JAMA Dermatol; 2015 May; 151(5):539-43. PubMed ID: 25671758
    [Abstract] [Full Text] [Related]

  • 11. The presence of anti-basement membrane zone antibodies in the sera of patients with non-bullous lupus erythematosus.
    Ishikawa O, Zaw KK, Miyachi Y, Hashimoto T, Tanaka T.
    Br J Dermatol; 1997 Feb; 136(2):222-6. PubMed ID: 9068736
    [Abstract] [Full Text] [Related]

  • 12. Clusters of clinical and immunologic features in patients with bullous systemic lupus erythematosus: experience from a single-center cohort study in China.
    Qiao L, Zhang B, Zheng W, Li M, Zhao Y, Zeng X, Zhang F, Wang L, Li L.
    Orphanet J Rare Dis; 2022 Jul 23; 17(1):290. PubMed ID: 35871005
    [Abstract] [Full Text] [Related]

  • 13. [Three cases of bullous lupus erythematosus].
    Jira M, Elqatni M, Sekkach Y, Elomri N, Mekouar F, Ghafir D.
    Ann Dermatol Venereol; 2013 Dec 23; 140(12):778-83. PubMed ID: 24315223
    [Abstract] [Full Text] [Related]

  • 14. Bullous systemic lupus erythematosus with lupus nephritis: a rare case of a subepidermal bullous disorder in a child.
    Poojary S, Rais S.
    Cutis; 2012 Jan 23; 89(1):17-21. PubMed ID: 22439305
    [Abstract] [Full Text] [Related]

  • 15. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
    Sawada K, Sawada T, Kobayashi T, Fujiki A, Matsushita T, Kawara S, Izumi K, Nishie W, Shimizu H, Takehara K, Hamaguchi Y.
    Immunol Med; 2021 Mar 23; 44(1):53-55. PubMed ID: 32634333
    [Abstract] [Full Text] [Related]

  • 16. Clinical features of newly diagnosed systemic lupus erythematosus after SARS-CoV-2 vaccination.
    Moriyama M, Noda K, Ito H, Matsushita T, Kurosaka D.
    Mod Rheumatol Case Rep; 2023 Dec 29; 8(1):63-68. PubMed ID: 37348045
    [Abstract] [Full Text] [Related]

  • 17. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
    Nishie W.
    Immunol Med; 2019 Mar 29; 42(1):22-28. PubMed ID: 31169082
    [Abstract] [Full Text] [Related]

  • 18. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis.
    Hinterseher J, Hertl M, Didona D.
    J Dtsch Dermatol Ges; 2023 Aug 29; 21(8):853-861. PubMed ID: 37218538
    [Abstract] [Full Text] [Related]

  • 19. Childhood-onset bullous systemic lupus erythematosus.
    Lourenço DM, Gomes RC, Aikawa NE, Campos LM, Romiti R, Silva CA.
    Lupus; 2014 Nov 29; 23(13):1422-5. PubMed ID: 25074872
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment of bullous lupus with corticosteroids and belimumab: A case report.
    Keshavamurthy C, Fibeger E, Virata A, Bansal P.
    Mod Rheumatol Case Rep; 2023 Jan 03; 7(1):52-56. PubMed ID: 35538618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.